| The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets K El, JD Douros, FS Willard, A Novikoff, A Sargsyan, D Perez-Tilve, ... Nature Metabolism 5 (6), 945-954, 2023 | 69 | 2023 |
| Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono-and dual-agonists A Novikoff, SL O'Brien, M Bernecker, G Grandl, M Kleinert, PJ Knerr, ... Molecular metabolism 49, 101181, 2021 | 59 | 2021 |
| Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice A Liskiewicz, A Khalil, D Liskiewicz, A Novikoff, G Grandl, G Maity-Kumar, ... Nature Metabolism 5 (12), 2075-2085, 2023 | 35 | 2023 |
| The molecular pharmacology of glucagon agonists in diabetes and obesity A Novikoff, TD Müller Peptides, 171003, 2023 | 29 | 2023 |
| GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice C Quarta, K Stemmer, A Novikoff, B Yang, F Klingelhuber, A Harger, ... Nature Metabolism 4 (8), 1071-1083, 2022 | 26 | 2022 |
| Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes R Sekar, K Motzler, Y Kwon, A Novikoff, J Jülg, B Najafi, S Wang, ... Cell metabolism 34 (11), 1824-1842. e9, 2022 | 16 | 2022 |
| Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity S Jall, M De Angelis, AM Lundsgaard, AM Fritzen, TS Nicolaisen, ... Diabetologia 63 (6), 1236-1247, 2020 | 13 | 2020 |
| Gut peptide agonism in the treatment of obesity and diabetes G Grandl, A Novikoff, R DiMarchi, MH Tschoep, TD Mueller Comprehensive Physiology 10 (1), 99-124, 2011 | 12 | 2011 |
| Neuronal loss of TRPM8 leads to obesity and glucose intolerance in male mice D Liskiewicz, Q Zhang, CS Barthem, M Jastroch, A Liskiewicz, N Khajavi, ... Molecular metabolism 72, 101714, 2023 | 10 | 2023 |
| TRPM7 kinase is required for insulin production and compensatory islet responses during obesity N Khajavi, A Beck, K Riçku, P Beyerle, K Jacob, SF Syamsul, A Belkacemi, ... JCI insight 8 (3), e163397, 2023 | 7 | 2023 |
| Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don’t A Novikoff, TD Müller Physiology, 2024 | 5 | 2024 |
| Why are we still in need for novel anti-obesity medications? A Novikoff, G Grandl, X Liu, TD Müller The Lancet Regional Health–Europe 47, 2024 | 2 | 2024 |
| Antagonizing GIPR adds fire to the GLP-1R flame A Novikoff, TD Müller Trends in Endocrinology & Metabolism, 2024 | 2 | 2024 |
| Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP: GLP-1 co-agonism without affecting body weight and food intake in mice S Akindehin, A Liskiewicz, D Liskiewicz, M Bernecker, C Garcia-Caceres, ... Molecular Metabolism 83, 101915, 2024 | 2 | 2024 |
| Global, neuronal or β cell-specific deletion of inceptor improves glucose homeostasis in male mice with diet-induced obesity G Grandl, G Collden, J Feng, S Bhattacharya, F Klingelhuber, ... Nature Metabolism 6 (3), 448-457, 2024 | 2 | 2024 |
| Recent achievements and future directions of anti-obesity medications G Grandl, A Novikoff, X Liu, TD Müller The Lancet Regional Health–Europe 47, 2024 | | 2024 |
| Signaling and trafficking dynamics of Estradiol-conjugated GLP-1 at the GLP-1R and subsequent intracellular events mediating estrogen liberation C Coupland, T Mueller, A Novikoff DIABETOLOGIA 67, S541-S542, 2024 | | 2024 |
| SURMOUNTing body weight barriers in type 2 diabetes A Novikoff, TD Müller Med 4 (12), 849-851, 2023 | | 2023 |
| Global, neuronal, and beta-cell specific deletion of insulin inhibitory receptor (incep-tor) improves glucose homeostasis in diet-induced obese mice G Grandl, G Colldén, A Ansarullah, W Xu, FF Far, T Gruber, ... | | 2022 |
| GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice C Quarta, K Stemmer, A Novikoff, B Yang, F Klingelhuber, A Harger, ... | | 2021 |
